

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Integrin β 2/CD18 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human Integrin β 1 or recombinant mouse Integrin α 5 is observed.
Source	Monoclonal Mouse IgG ₁ Clone # 212701
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Integrin β 2/CD18 Gln23-Asn700 Accession # AAA59490
Conjugate	Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 μ g/10 ⁶ cells	Human peripheral blood mononuclear cells

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

Integrin α X β 2, also called CD11c/CD18, p150/95 or complement receptor type 4 (CR4), is one of four β 2 integrins. The non-covalent heterodimer of 150 kDa α X/CD11c and 95 kDa β 2/CD18 integrin subunits is expressed on macrophages, dendritic cells and hairy cell leukemias, with lower amounts on other myeloid cells and activated B, NK and some cytotoxic T cells (1-7). Like other integrins, α X β 2 has multiple activation states (3). In the presence of divalent cations and "inside-out" signaling, α X β 2 is fully active and extended. The α X vWFA or I-domain, which contains the adhesion sites, forms the N-terminal head region with the α X beta-propeller and the β 2 vWFA domain (1, 8). In the inactive state, the heterodimer flexes in the center at the α X thigh and calf domains and β 2 I-EGF domains, impeding access to adhesion sites (1). The 1088 aa human α X/CD11c ECD shares 70-76% aa sequence identity with mouse, rat and canine α X while the 678 aa human β 2/CD18 ECD shares 81-83% aa sequence identity with mouse, rat, cow, dog, goat, sheep, and pig β 2. Potential α X isoforms containing 719 and 725 aa (as compared to full-length 1163 aa α X) lack the vWFA domain and the N-terminus. Active α X β 2 shares some adhesion partners with α M β 2/CD11b/CD18, including complement opsonin fragment iC3b, ICAMs, vWF and fibrinogen, and is expressed on many of the same cells (4-11). However, α M β 2 activity is often constitutive, while α X β 2 activity requires cell activation (4-7). α X β 2 also binds osteopontin, Thy-1, plasminogen, heparin, and proteins with abnormally exposed acidic residues (11-16). The adhesion events are important for proliferation, degranulation, chemotactic migration, and phagocytosis of complement-opsonized particles (5, 6, 9, 11, 12, 16). Mutations of β 2, especially in the vWFA domain, cause leukocyte adhesion deficiency (LAD-1) and susceptibility to bacterial infections (17).

References:

1. Corbi, A.L. *et al.* (1987) EMBO J. **6**:4023.
2. Kishimoto, T.K. *et al.* (1987) Cell **48**:681.
3. Hynes, R.O. (2002) Cell **110**:673.
4. Arnaout, M.A. (1990) Blood **75**:1037.
5. Postigo, A.A. *et al.* (1991) J. Exp. Med. **174**:1313.
6. Beyer, M. *et al.* (2005) Respir. Res. **6**:70.
7. Nicolaou, F. *et al.* (2003) Blood **101**:4033.
8. Vorup-Jensen, T. *et al.* (2003) Proc. Natl. Acad. Sci. USA **100**:1873.
9. Bilisland, C.A.G. *et al.* (1994) J. Immunol. **152**:4582.
10. Pendu, R. *et al.* (2006) Blood **108**:3746.
11. Sadhu, C. *et al.* (2007) J. Leukoc. Biol. **81**:1395.
12. Schack, L. *et al.* (2009) J. Immunol. **182**:6943.
13. Choi, J. *et al.* (2005) Biochem. Biophys. Res. Commun. **331**:557.
14. Gang, J. *et al.* (2007) Mol. Cells **24**:240.
15. Vorup-Jensen, T. *et al.* (2007) J. Biol. Chem. **282**:30869.
16. Vorup-Jensen, T. *et al.* (2004) Proc. Natl. Acad. Sci. USA **102**:1614.
17. Kishimoto, T.K. *et al.* (1987) Cell **50**:193.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.